Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study
Albiges, L. Beckermann, K. Miller, W. H. Goh, J. C. Gajate, P. Harris, C. A. Suárez, C. Peer, A. Park, S. H. Stadler, W. M.
Albiges, L.
Beckermann, K.
Miller, W. H.
Goh, J. C.
Gajate, P.
Harris, C. A.
Suárez, C.
Peer, A.
Park, S. H.
Stadler, W. M.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Albiges L, Beckermann K, Miller WH, Goh JC, Gajate P, Harris CA, et al. Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772001041.